Kangmei Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 600518.SS

Kangmei Pharmaceutical Co., Ltd. Capital Expenditure for the year ending December 31, 2023: USD -14.05 M

Kangmei Pharmaceutical Co., Ltd. Capital Expenditure is USD -14.05 M for the year ending December 31, 2023, a -101.49% change year over year. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Kangmei Pharmaceutical Co., Ltd. Capital Expenditure for the year ending December 31, 2022 was USD -6.97 M, a 74.19% change year over year.
Kangmei Pharmaceutical Co., Ltd. Capital Expenditure for the year ending December 31, 2021 was USD -27.01 M, a 41.57% change year over year.
Kangmei Pharmaceutical Co., Ltd. Capital Expenditure for the year ending December 31, 2020 was USD -46.22 M, a 31.97% change year over year.
Kangmei Pharmaceutical Co., Ltd. Capital Expenditure for the year ending December 31, 2019 was USD -67.95 M, a 89.83% change year over year.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

Shanghai Stock Exchange: 600518.SS

Kangmei Pharmaceutical Co., Ltd.

CEO	Mr. Guowei Liu
IPO Date	March 19, 2001
Location	China
Headquarters	East side of Jieshen Road
Employees	4,409
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Kangmei Pharmaceutical Co., Ltd. produces and sells Chinese medicines in China. It also offers chemical drug products; and operates hospitals and Chinese medicine pharmacies. The company was founded in 1997 and is headquartered in Puning, China.

Key trends

Past 5 years